natgillin/translations-raw huggingface dataset:
In another preferred embodiment, the pain to be treated and/or the chronification of which is to be inhibited is selected from the group consisting of postoperative pain, inflammatory pain, migraine-related pain, headache-related pain, irritable bowel syndrome-related pain, fibromyalgia-related pain, arthritic pain, skeletal pain, joint pain, gastrointestinal pain, muscle pain, angina pain, facial pain, pelvic pain, claudication, postoperative pain, post traumatic pain, tension-type headache, obstetric pain, gynecological pain, and chemotherapy-induced pain. 
Tapentadol za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je bol izabrana iz grupe koja se sastoji od postoperativne boli, upalne boli, boli povezane s migrenom, boli povezane s glavoboljom, boli povezane sa sindromom iritabilnog crijeva, boli povezane s fibromialgijom, artritične boli, koštane boli, boli u zglobovima, gastrointestinalne boli, mišićne boli, boli uslijed angine, boli u licu, boli u zdjelici, klaudikacije, postoperativne boli, posttraumatske boli, tenzijske glavobolje, opstetričke boli, ginekološke boli, i boli inducirane kemoterapijom.
The method of claim 1, wherein the compound is administered in the form of a transdermal patch. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da je u obliku transdermalnog flastera, masti, losiona, kreme ili gela.
The pharmaceutical composition according to claim 7, for use in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. 
Farmaceutske kompozicije u skladu sa zahtjevom 6, za primjenu u terapiji ne-Hodgkinovog limfoma i kronične limfocitne leukemije.
The method of claim 1 wherein the pharmaceutical composition further comprises at least one humectant and at least one emollient. 
najmanje jedno sredstvo za zakiseljavanje; i najmanje jedno farmaceutski prihvatljivo nevodeno otapalo, naznačen time, što:
a light chain region comprising the amino acid sequence of SEQ ID NO:99; a light chain region comprising the amino acid sequence of SEQ ID NO:100; or a light chain region comprising the amino acid sequence of SEQ ID NO:101. 
(10) područje slabog lanca, koje sadrži aminokiselinsku sekvencu SEQ ID NO:99; (11) područje slabog lanca, koje sadrži aminokiselinsku sekvencu SEQ ID NO:100; ili (12) područje slabog lanca, koje sadrži aminokiselinsku sekvencu SEQ ID NO: 101.
A method for automatic adaptation of the properties of a bed arrangement, comprising the steps: 
Metoda za automatsku prilagodbu svojstava kreveta, koja sadrži korake:
The use of item 14 or 15, wherein the patient is selected from a Type 1-diabetic patient, a Type 2-diabetic patient, in particular a diet-treated Type 2-diabetic patient, a sulfonylurea-treated Type 2-diabetic patient, a far-advanced stage Type 2-diabetic patient and/or a long-term insulin-treated Type 2-diabetic patient. 
Uporaba prema zahtjevu 13 ili 14, naznačena time što je pacijent odabran od pacijenta s dijabetesom tipa 1, pacijenta s dijabetesom tipa 2, posebno s dijabetesom tipa 2 liječenog ishranom, pacijenta s dijabetesom tipa 2 liječenog sulfonilureom, pacijenta s dijabetesom tip 2 u daleko uznapredovalom stadiju i/ili pacijenta s dijabetesom tip 2 dugotrajno liječenog inzulinom.
However the presence of an abstinence syndrome is not the most essential component of addiction, as addiction is “a behavioral pattern characterized by compulsive use of a drug and overwhelming involvement with its procurement and use” despite known harmful effects (Goodman & Gillman's The Pharmacological Basis of Therapeutics, J. G. Hardman (Ed. 
Ipak, prisutnost apstinencijskog sindroma nije najbitnija komponenta ovisnosti, pošto je ovisnost "uzorak ponašanja karakteriziran kompulzivnom upotrebom droge te neodoljivim angažiranjem oko njene nabave i upotrebe" usprkos poznatim štetnim učincima (Goodman & Gillman, The Pharmacological Basis of Therapeutics, J. G. Hardman (Ur.
The reaction bottle was sealed and warmed at 90° C. with stirring for 20 h. 
Reakcijska boca je zatvorena i zagrijavana na 90*C uz miješanje 20 sati.
% (w/v) olopatadine free base or an equivalent amount of a pharmaceutically acceptable salt of olopatadine; 
0,6% (tež./vol.) slobodne baze olopatadina ili ekvivalentne količine farmaceutski prihvatljive soli olopatadina;
selecting an antibody producing cell which produces an antibody which binds to human ILT7 from the antibody producing cell of the immune animal. 
(2) odabir jedne stanice, koja proizvodi antitijelo koje se veže na humani ILTY7, iz stanice imune životinje koja proizvodi to antitijelo.
The method of claim 2, wherein the additional therapeutic agent is an anti-angiogenic agent or a chemotherapeutic agent. 
Modificirana fuzija između topivog FGF receptora i Fc u skladu s patentnim zahtjevom 32, naznačena time što navedeno dodatno terapijsko sredstvo je antiangiogeno sredstvo ili kemoterapijsko sredstvo.
placing a strip of a desiccant polymer or a desiccant film in direct contact with the homogeneous suspension in said bottle before sealing the bottle. 
C) = postavljanje trake polimera za sušenje ili filma za sušenje u izravni dodir s homogenom suspenzijom u navedenoj boci prije zatvaranja boce.
The topical veterinary composition of clause 10, wherein the at least second active agent is an anthelmintic active agent selected from thiabendazole, oxibendazole, mebendazole, fenbendazole, oxfendazole, albendazole, triclabendazole, febantel, levamisole, pyrantel, morantel, praziquantel, closantel, clorsulon, an amino acetonitrile active agent, or an aryloazol-2-yl cyanoethylamino active agent. 
Topikalni veterinarski pripravak prema zahtjevu 7, naznačen time, da najmanje druga djelatna tvar je antihelmintska djelatna tvar odabrana od tiabendazola, oksibendazola, mebendazola, fenbendazola, oksfendazola, albendazola, triklabendazola, febantela, levamisola, pirantela, morantela, prazikvantela, klozantela, klorsulona, djelatne tvari aminoacetonitrila, i djelatne tvari ariloazol-2-il-cijanoetilamina.
A method according to any of the claims 1-5, wherein the subject is a human individual which has been vaccinated against rabies. 
Postupak prema zahtjevu 1, 2 ili 3, naznačen time da je subjekt čovjek pojedinac koji je bio cijepljen protiv bjesnoće.
The compound according to claim 7, wherein R2 is 3-F or 2-OH. 
Spoj u skladu s patentnim zahtjevom 6, naznačen time da R2 je 3-F ili 2-OH.
The imaging material supply cartridge of claim 1, wherein each and every data field grouping has a different access mode and a different encryption attribute. 
Spremišna patrona za materijal za pisanje (24) u skladu s patentnim zahtjevom 1, naznačena time što svaka od grupacija podatkovnih polja ima poseban pristupni način i poseban enkripcijski atribut.
Blade of a wind turbine according to any of the preceding claims, wherein saidvortex generator is fixed on the airfoil surface and said baseplate, said fins and said surface form a solid body without air inclusions. 
Lopatica vjetroturbine prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da je navedeni vrtložni generator pričvršćen na površinu propelera i navedene osnovne podloge, navedena peraja 1 navedena površina formiraju čvrsto tijelo bez utjecaja zraka.
The typical daily dose of the active substance varies within a wide range and will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. 
Tipična dnevna doza aktivnog sastojka varira u širokom rasponu i može ovisiti o brojnim čimbenicima poput, na primjer pojedinačnih zahtjeva svakog pacijent, načina primjene i same bolesti.
The inventors of the present invention have surprisingly found out that proteins showing active thermostabilization also show temperature stability. This was shown by the following example. The inventors generated a GH7 endoglucanase, that is a particular variant of SEQ ID NO: 4 (i.e. the one given by SEQ ID NO: 2) as follows. 
ID NO.: 2, naznačen time, da protein pokazuje barem 90 %-tni kapacitet pretvorbe preostalog supstrata na temperaturi od 60 *C, kada se inkubacija provodi tijekom jednog sata. Protein u skladu s patentnim zahtjevom 1, naznačen time, da je to protein identičan sa SEQ ID NO: 6; SEQ ID NO: 7;
A compound according to claim 1, wherein R9 is a straight or branched C1-C9 alkyl. 
R9 je ravan ili razgranati C1-C9 alkil, supstituiran grupom opće formule (V):
Aspirate cell culture media off the 15 cm2 plates, rinse with 5 mL cold PBS and aspirate. 
* > Aspiriraj medij stanične kulture sa 15 cm" ploče, isperi sa 5 ml hladne PBS i aspiriraj
The composition for use according to claim 4, wherein said liquid formulation is selected from the group consisting of oral solutions, suspensions, emulsions and syrups. 
Smjesa za uporabu prema zahtjevu 4, gdje se tekući oblik izabire iz grupe koja obuhvaća oralne otopine, suspenzije, emulzije 1 sirupe.
The dental post according to claim 1, wherein said resin matrix comprises a dimethacrylate compound. The dental post according to claim 1, wherein a fraction in a range of at least 40% and at most 80% by volume of a total content of said dental post comprises said fibres. 
Zubni most u skladu s najmanje jednim od patentnih zahtjeva 1 do 6, naznačen time što udio od najmanje 40% 1 najviše 80%, volumno, ukupnog sadržaja navedenog mosta čine navedena vlakna (8).
Process for the preparation of the formulations in accordance with claims 1 to 15 characterized in that comprises the steps of: 
Postupak priprave formulacija u skladu s patentnim zahtjevima 1 do 10, naznačen time što se sastoji u koracima:
solution, emulsion or suspension. 
otopine, emulzije 1 suspenzije.
transmitting said amount (L) of said periodically measured and stored consumption data to said concentrator (C). 
- prijenosa navedene količine (L) navedenih periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju u navedeni sabirnik (C).
is —NH2, and is the C-terminal group of the peptidic compound and is selected from —OH and —NH2. 
predstavlja C-terminalnu skupinu peptidnog spoja i odabrana je od OH i NH2, ili njegova sol ili solvat, pri čemu spoj je agonist GLP-1 i GIP receptora.
The procedure is modified from published protocols (W. Zhou et al; J. Biol. 
Postupak je modificiran iz objavljenih protokola (W. Zhou i suradnici: J. Biol.
The treatment would be maintained until such time as the patient was deemed ready for down-titration. 
Liječenje se treba održavati do trenutka kada će se prosuditi da je pacijent spreman na smanjivanje doze.
The process of claim 11, wherein the stainless steel comprises an austenitic stainless steel and the second mixture comprises HNO3 and HF, and wherein the concentration of HF in the second mixture is in the range of from 5 g/L to 25 g/L. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što nehrđajući čelik sadrži austenitni nehrđajući čelik, a druga smjesa sadrži HNO; i HF, te gdje je koncentracija HF u drugoj smjesi u rasponu od 5 g/l do 25 g/l.
The mice were placed in a transparent plastic box of floor dimensions 30 x 30 cm in a room with low light intensity (maximum 20 lux). 
Miševi su smješteni u prozirnu plastičnu kutiju tlocrta 30 x 30 cm u sobi s niskim intezitetom svjetla (najviše 20 luksa).
A compound according to claim 32 wherein R4 is phenyl substituted at the 4-position with hydroxy, C1-3alkylaminocarbonyl, or aminocarbonyl, and substituted at the 2- and 6- positions with methyl substituents. 
Spoj prema zahtjevu 32 naznačen time da R4 je fenil supstituiran na 4-poziciji sa hidroksi, C1-3alkilaminokarbonil ili aminokarbonil i supstituiran na 2-poziciji i 6-poziciji sa metil supstituentima.
Preferably said combination is used for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with the bacterial infection. 
4. - Kombinacija prema zahtjevu 1 ili zahtjevu 2 naznačena time da je za upotrebu za ubijanje ne-multiplicirajućih mikroorganizama povezanih s mikrobnom infekcijom.
The compound for use in a method of treatment according to claim 8 or the use of claim 9, further comprising administering to the subject an additional therapeutic agent, optionally wherein the additional therapeutic agent is a different Raf kinase inhibitor or an inhibitor of MEK, mTOR, HSP90, AKT, PI3K, CDK9, PAK, Protein Kinase C, a MAP kinase, a MAPK Kinase, or ERK, and the additional therapeutic agent is administered to the subject concurrently with the compound. 
Spoj za uporabu u postupku liječenja prema zahtjevu 11 ili uporaba prema zahtjevu 12, naznačen/a time, da postupak nadalje obuhvaća primjenu dodatnog terapeutskog sredstva na pojedincu, pri čemu se dodatno terapeutsko sredstvo na pojedincu opcijski primjenjuje istovremeno sa spojem.
A method of making a genetically modified mouse, comprising modifying the genome of a mouse by replacing a mouse genomic fragment coding for a mature mouse IL-15 polypeptide at the endogenous mouse IL-15 locus with a human genomic segment coding for a mature human IL-15 polypeptide wherein the human IL-15 exons in said human genomic segment consist of human IL-15 protein-coding exons 3, 4, 5 and 6, to form a humanized IL-15 gene, wherein the IL-15 exons are numbered with the first coding exon as exon 1, and wherein the humanized IL-15 gene is under control of all endogenous mouse IL-15 upstream regulatory elements at the endogenous mouse IL-15 locus. 
Postupak dobivanja gentički modificiranog miša, naznačen time što se sastoji u modificiranju mišjeg genoma zamjenom mišjeg genomskog fragmenta koji kodira zreli mišji polipeptid IL-15 na endogenom mišjem lokusu IL-15 ljudskim genomskim segmentom koji kodira zreli ljudski polipeptid IL-15, gdje ljudske egzone u IL-15 u navedenom ljudskom genomskom segmentu čine ljudski egzoni 3, 4, 5 1 6 koji kodiraju protein IL-15, kako bi se dobilo humanizirani gen za IL-15, gdje su egzoni u IL-15 tako obrojčani da je prvi kodirajući egzon egzon 1, te gdje je humanizirani gen za IL-15 pod kontrolom svih endogenih mišjih uzvodnih regulacijskih elemenata za IL-15 na endogenom mišjem lokusu IL-15.
The mixture is then reacted and excess phosphorus trichloride is removed. 
Smjesa se potom stavi u reakciju i suvišak fosfor-triklorida se ukloni.
Table 1A: Crystallographic data concerning the unit cells of asenapine maleate monoclinic form and orthorhombic form 
Tablica 1A: Kristalografski podaci koji se odnose na jedinične stanice asenapin maleata monoklinskog i ortorombskog oblika
a processor which is configured for generating values of restored pixels of a current block by performing deblocking-filtering on values of pixels of the current block and determining a correction type of pixel values and generating information about the correction type of pixel values to indicate one of a band type and an edge type; 
Postupak dekodiranja video zapisa, te postupak sadrži: dobivanje, iz toka bitova, informacije o vrsti korekcije vrijednosti piksela; kada informacija o vrsti korekcije vrijednosti piksela i upućuje na jedan od pojasnog tipa i rubnog tipa, dobivanje mnoštva kompenzacijskih vrijednosti iz toka bitova;
purifying the salt of the compound of formula (V), by crystallization of the salt of the compound of formula (V) in an organic solvent or a mixture of an organic solvent and water in the presence of an acid to form the neutral form of the compound of formula (V). 
Cc) - pročišćavanje soli spoja s formulom (V), kristalizacijom soli spoja s formulom (V) u organskom otapalu ili smjesi organskog otapala i vode u prisutnosti kiseline, da se dobije neutralni oblik spoja s formulom (V).
An isolated monoclonal antibody that selectively binds to ABCB5 comprising an immunoglobulin heavy chain variable domain having a CDR1-H1 which comprises the amino acid sequence DYYMY, a CDR2-H2 which comprises the amino acid sequence TINDGGTHTY, and a CDR3-H3 which comprises the amino acid sequence DDYYYGSHFDAMDY and an immunoglobulin light chain variable domain, having a CDR1-L1 which comprises the amino acid sequence RASKSVSTSGYSYMH, a CDR2-L2 which comprises the amino acid sequence LVSNLES, and a CDR3-L3 which comprises the amino acid sequence QHIRELTR. 
HR P20181385 T1 PATENTNI ZAHTJEVI Izolirano monoklonsko protutijelo koje se selektivno veže na ABCB5 naznačeno time da sadrži varijabilnu domenu teškog lanca imunoglobulina koja ima CDR1-H1 koja sadrži aminokiselinsku sekvencu DYYMY, CDR2- H2 koja sadrži aminokiselinsku sekvencu TINDGGTHTY, i CDR3-H3 koja sadrži aminokiselinsku sekvencu DDYYYGSHFDAMDY i varijabilnu domenu lakog lanca imunoglobulina, koja ima CDRI-L1 koja sadrži aminokiselinsku sekvencu RASKSVSTSGYSYMH, CDR2-L2 koja sadrži aminokiselinsku sekvencu LVSNLES, i CDR3-L3 koja sadrži aminokiselinsku sekvencu QHIRELTR.
Accordingly, the present invention provides a bifunctional molecule comprising a polypeptide binding partner specific for a given pMHC epitope, and an immune effector polypeptide, the N-terminus of the pMHC binding partner being linked to the C-terminus of the immune effector polypeptide, PROVIDED THAT the said polypeptide binding partner is not a T-cell receptor comprising the alpha chain SEQ ID No: 7 and the beta chain SEQ ID No: 9. As mentioned, the polypeptide pMHC binding partner may be an antibody or a TCR. Thus in one embodiment of the invention the pMHC binding partner is a heterodimeric aB TCR polypeptide pair, or a single chain aB TCR polypeptide, and the N-terminus of the a or B chain of the heterodimeric TCR polypeptide pair, or the N-terminus of the scTCR polypeptide, is linked to a C-terminal amino acid of the immune effector polypeptide. 
Bifunkcionalna molekula koja sadrži polipeptidni vezivajući partner specifičan za navedeni pMHC epitop, i imuni efektorni polipeptid, pri čemu je N-terminus pMHC vezivajućeg partnera vezan za C-terminus imunog efektornog polipeptida, UZ UVJET DA navedeni polipeptidni vezivajući partner nije T-stanični receptor koji sadrži alfa lanac SEQ ID No: 7 i beta lanac SEQ ID No: 9, pri čemu pMHC vezivajući partner je heterodimerni aB TCR polipeptidni par, ili jednolančani af TCR polipeptid, i N-terminus o. ili B lanca heterodimernog TCR polipeptidnog para ili Nterminus sc TCR polipeptida, je vezan sa C-terminalnom aminokiselinom imunog efektornog polipeptida i pri čemu imuni efektorni polipeptid je antitijelo koje se specifično veže za antigen predstavljen preko T-stanice.
The child-resistant blister pack (1) as claimed in claim 1, wherein the pack (1) comprises at least four unit package regions (2, 4a). 
Blister pakiranje koje djeca ne mogu otvoriti (1) kako se navodi u patentnom zahtjevu 1, naznačeno time, da pakiranje (1) sadrži najmanje četiri područja za pakiranje pojedinačnih doza (2, 44).
This may be performed by monitoring the location and possible directions of the vehicle 2 based on the position data. Thus, the signalling means 18 may be adapted to provide a changing speed limit warning to alert the user that a different imposed speed limit will be enforced in the next stretch of road. 
Sustav prema zahtjevu 1, naznačen time što je sustav konfiguriran da osigura sustav predviđanja ili predupozorenja, te su signalna sredstva (18) prilagođena da osiguravaju promjenu upozorenja o ograničenju brzine kako bi upozorili korisnika da će na sljedećem dijelu ceste biti provođeno drugačije nametnuto ograničenje brzine.
The Apparatus of claim 1, the apparatus further comprising: a repeating module configured to add Layer 1 header to the time interleaved Layer 1 signaling data, wherein the Layer 1 header includes Layer 1 time interleaving information which indicates the time interleaving depth. 
Uređaj iz patentnog zahtjeva 1, uređaj nadalje obuhvaća: modul za ponavljanje konfiguriran za dodavanje zaglavlja razine 1 u signalni podatak razine 1 s umetnutim vremenom, pri čemu zaglavlje razine 1 uključuje informaciju umetanja vremena razine 1 koja ukazuje na dubinu umetanja vremena.
A light source as claimed in claim 16, claim 17 or claim 18, wherein the plug is flush with the crucible at outer surfaces thereof. 
Svjetlosni izvor u skladu s patentnim zahtjevom 16, patentnim zahtjevom 17 ili s patentnim zahtjevom 18, naznačen time, da je čep poravnat s vanjskom površinom retorte.
Examples of different environments, applications, and configurations are set forth in Ser. No. 10/140,596. 
Primjeri različitih okolina, primjena i konfiguracija iznijeti su u Serial Number 10/140,596.
The antibiotic is present in an amount of from about 1 wt. % to about 80 wt. %, based on the total weight of the coated micropellet. 
Antibiotik je prisutan u količini od oko 1 maseni % do oko 80 masenih %, na osnovi ukupne mase obloženih mikropeleta.
In further embodiments, the hemihydrate has an X-ray powder diffraction pattern comprising peaks, in terms of 20, at about 13.7°, about 14.9°, about 15.4°, about 15.8°, and about 16.7°. 
Hemihidrat u skladu sa zahtjevom 1, naznačen time, da ima uzorak difrakcije praha X-zrakama koji sadrži pikove, u značenju 20, na oko 13.7%, oko14.9%, oko 15.4%, oko 15.8%, oko 16.7, oko 20.1% i oko 21.4".
A dosage form according to claim 9, characterized in that it is suitable for oral, intravenous, intraarterial, intraperitoneal, intradermal, transdermal, intrathekal, intramuscular, intranasal, transmucosal, subcutaneous, or rectal administration. 
Oblik doziranja prema zahtjevu 6, naznačen time da je prikladan za oralno, intravenozno, intraarterijalno, intraperitonealno, intradermalno, transdermalno, intramuskularno, intratekalno, intranazalno, transmukozno, potkožno, ili rektalno davanje.
a chamber configured to contain a mixture of organic mass and one or more micro-organisms selected to degrade the organic mass wherein the chamber includes: a U-shaped container having a curved bottom, and 
komoru (106) za sadržavanje smjese organske mase i jednoga ili više mikroorganizama koji su odabrani za razgradnju organske mase; i napravu za miješanje (120) koja je izvedena u komori u svrhu miješanja smjese, pri čemu naprava za miješanje obuhvaća:
To a 12×75 mm polyethylene test tube is added 100 ul of sample medium diluted 1:5 or rLH standard in RIA buffer and 100 ul of [125I]-labeled rLH (˜30,000 cpm) plus 100 ul of rabbit anti-rLH antibody diluted 1:187,500 and 100 ul RIA buffer. 
U polietilensku epruvetu dimenzija 12 x 75 mm dodano je 100 pd uzorka medija razrijeđenog 1:5, ili LH standarda u RIA puferu i 100 ul ['"I]-obilježenog rLH (30.000 otkucaja u minuti), uz dodatak 100 ul kunićjeg protu-rLH protutijela, razrijeđenog 1:187,500 1 100 ul RIA pufera.
After stirring at 0 °C for 10 minutes, the reaction mixture is allowed to warm to room temperature overnight and then diluted with DCM (3 ml). 
Nakon miješanja 10 minuta pri OC, reakcijsku smjesu se pusti preko noći zagrijati na sobnu temperaturu i zatim se razrijedi s DCM-om (3 ml).
wherein the glyoxalated copolymer composition comprises: the glyoxalated copolymer composition according to claim 1 . The method of making paper or board according to claim 16, wherein the glyoxalated copolymer composition is combined with the cellulose fibers or applied to the wet or dry web paper or wet or dry board in amounts ranging from about 0.1 to about 20 pounds dry copolymer per ton of a dry paper furnish. 
Postupak proizvodnje papira ili ploče prema zahtjevu 14, gdje se sastav glioksaliranog kopolimera kombinira s vlaknima celuloze ili nanosi na mokri ili suhi mrežasti papir ili mokru ili suhu ploču u količinama u rasponu od 0,1 do 20 funti (0,5-10 kg) suhog kopolimera po toni materijala suhog papira, poželjno 1 do 12 (0,5-6 kg), najpoželjnije 1 do 9 (0,5-4,5 kg), posebno 1 do $ funti (0,5-4 kg) suhog kopolimera po toni suhog materijala.